BioVaxys Technology Corp. announced that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps. The partnership between BioVaxys and Procare for the EU clinical development of BioVaxys' ovarian cancer vaccine BVX-0918 will continue and remains unchanged.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.07 CAD | 0.00% | -6.67% | +40.00% |
1st Jan change | Capi. | |
---|---|---|
+40.00% | 10.85M | |
+7.92% | 113B | |
+10.37% | 106B | |
+0.41% | 22.27B | |
-12.08% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.92% | 17.24B | |
+7.20% | 14.29B | |
+36.74% | 12.52B |
- Stock Market
- Equities
- BIOV Stock
- News BioVaxys Technology Corp.
- BioVaxys Technology Corp. and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare and Immunocaps